With the launch of our new, mobile-friendly website in October 2020, we have decided to retire or “sunset” the MotherToBaby App for both iOS and Android. By February 28, 2021, the MotherToBaby App will no longer be available for download from Apple’s App Store or from the Google Play Store. If you are a current MotherToBaby App User: The app is no longer being supported or updated, so we highly recommend deleting it from all of your devices. How Do I Prepare for the Change? Bookmark …
Press Releases: OTIS
Webinar Recording: Pregnancy and Lactation Tidbits
Access our free presentation for healthcare professionals on current issues from ADHD medications, the risks of vaping, and cannabis use during pregnancy and lactation. Filmed on August 25, 2020, a link to the recording can be found here. …
OTIS Releases Statement on Anti-Racism
The Organization of Teratology Information Specialists (OTIS), the professional society that provides the MotherToBaby service, has released the following statement on anti-racism: In light of the horrifying recent events taking place in our country, which is only the latest in a long history of violence against Black men, women, and children, we think as an organization it is important to state that diversity, equality, inclusion, and respect are of the upmost importance to OTIS. As a …
Coronaviruses and Pregnancy Statement from MotherToBaby Experts
We know pregnant women are concerned about the newly described coronavirus. MotherToBaby and the CDC are monitoring the situation and will educate people if there is new evidence about a danger from a coronavirus infection that would be specific to the unborn baby. You can find more information on your common questions about the coronavirus through our fact sheet at: https://mothertobaby.org/fact-sheets/covid-19/. In the meantime, common strategies to avoid getting sick include thoroughly …
Study Suggests Adalimumab Exposure in Pregnancy Does Not Increase Birth Defects Risk
602 Pregnancies Examined by the Non-Profit Organization of Teratology Information Specialists LA JOLLA, CA –A new study conducted by birth defects experts from the Organization of Teratology Information Specialists (OTIS) suggests adalimumab use in pregnancy was not associated with an increased risk for adverse outcomes examined, such as major structural birth defects, spontaneous abortion and preterm delivery. The findings were published today in the Public Library of Science (PLOS) One …
